# A First-in-human (FIH), Open-Label, Dose Escalation and Expansion Cohorts Study of MC002

> clinical trial · VERIFIED · 2026-07-24

Status: NOT_YET_RECRUITING · Sponsor: Hangzhou MacroLink Biopharmaceutical LLC · Condition: Advanced Esophageal Cancer

- Company: Hangzhou MacroLink Biopharmaceutical LLC
- Sector: Advanced Esophageal Cancer
- Primary source: https://clinicaltrials.gov/study/NCT07726212

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.